SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- HIV -- Ignore unavailable to you. Want to Upgrade?


To: idos who wrote (115)8/15/2009 1:44:37 PM
From: Elroy Jetson  Read Replies (1) | Respond to of 155
 
Isentress (raltegravir) is showing poor clinical durability, with patients quickly developing viral resistance within a year.

If elvitegravir does not prove to be more durable, as promised, these two are but a temporary stop-gap measures.
.